new delhi, Jan. 6 -- Facing mounting scrutiny over drug safety lapses, India is working to overhaul its pharmaceutical licensing framework by introducing a separate wholesale licensing regime for bulk drugs, active pharmaceutical ingredients (APIs) and key starting materials (KSMs), according to three government officials and documents reviewed by Mint. A draft notification is in the works for a new licensing regime, the people cited above said on the condition of anonymity. This will dismantle the current common licensing system for raw materials and finished medicines, give the Drugs Controller General of India (DCGI) a long-missing registry of nearly 1.2 million bulk drug traders, and significantly strengthen traceability and accountabil...